MilliporeSigma Articles
-
Viral Vectors: Are We There Yet?
10/21/2022
What must we do as an industry to continue the momentum of cell and gene therapies and ensure these revolutionary treatments become a reality for patients who need them?
-
Biosafety Testing And Quality Control Requirements For Lentiviral Vectors
9/26/2022
Learn more about manufacturing principles of LV vectors as well as testing requirement regulatory considerations with a particular focus on the replication competent virus assay and infectious titer assay.
-
Using Next Generation Sequencing Methods For Virus Vector Identity Testing
9/7/2022
Sequencing techniques play a crucial role in establishing the quality attributes of a variety of therapeutic products. Learn what advantages NGS offers for obtaining accurate sequences.
-
Data Utilization For Advanced Analytics And Near Real-Time Monitoring
8/16/2022
Control, monitor, and analyze equipment, processes, results, and data in near real time and make data-driven decisions at both the process and plant levels.
-
Navigating The Regulatory Maze: Fundamentals For Drug Development
7/15/2022
Learn about key regulatory concepts and ways to accelerate and reduce risk throughout the drug development journey.
-
Remote Access And Monitoring Of Bioprocess Unit Operations
5/26/2022
Digital transformation projects require a scalable connectivity solution for the manufacturing floor that is easily and rapidly deployed. Explore elements that enable connectivity among equipment.
-
Utilizing Multiple Tech Providers In Gene Therapy Manufacturing
5/19/2022
With a diverse landscape of potential partners, it is important to know what qualities to look for in a technology provider and how to traverse the challenges inherent in managing multiple relationships.
-
Trends In The Outsourcing Of Development And Manufacturing Of Biologics
3/18/2022
Read more on trends related to outsourcing and share what attributes of an outsourcing partner are sought by developers and manufacturers of biopharmaceuticals.
-
Development Of A Novel Sf9 Rhabdovirus-Negative Cell Line (Sf-RVN®) And Companion Chemically Defined Medium
3/15/2022
This whitepaper describes the development of a novel Sf-RVN® cell line, with companion chemically defined medium, the EXCELL® CD Insect Cell Medium which can be combined and offer a Sf-Rhabdovirus free alternative for the BICS production of biologics.
-
A Multifaceted Strategy For Viral Safety In AAV Processes
3/10/2022
Assurance of viral clearance can be difficult, however, during production of vectors such as adeno-associated viruses (AAV) used for the purpose of gene delivery. The need to define and deploy an appropriate and robust viral clearance strategy can be particularly challenging without an overarching strategy in place.